Article
27 Oct 2025
Xbrane Enters Into Conditional Financing Deal Related To Ranibizumab Biosimilar
AUTHORS CONTENT
Article
02 Apr 2025
Henlius Receives Orphan-Drug Designation For HLX22 (Anti-HER2 MAb) For Gastric Cancer
Article
04 Nov 2024
Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar
Article
20 Sep 2024
Alteogen Seeks Approval For Aflibercept Biosimilar In Korea
Article
15 Aug 2024
FDA Approves Sandoz's ENVEEZU™ (Aflibercept-abzv)
Article
15 Jul 2024
Outlook Therapeutics Announces UK MHRA Marketing Authorization Of LYTENAVA™ (Bevacizumab Gamma)
Article
11 Jun 2024
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar
Article
07 May 2024
PTAB Issues Final Written Decisions Finding Claims Of Recombinant Lentiviral Vector Patents Valid
Article
03 Apr 2024
FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy
Article
05 Mar 2024
FDA Approves First Cellular Therapy For Treatment Of Unresectable Or Metastatic Melanoma
Article
26 Jan 2024
PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid
Article
21 Dec 2023
Recent Biosimilar Approvals
Article
06 Oct 2023
Biogen Announces FDA Approval Of TOFIDENCE, A Tocilizumab Biosimilar Referencing ACTEMRA
Article
04 Sep 2023
PTAB Issues Final Written Decisions Finding Claims Of Tocilizumab-related Patents Invalid
Article
01 Aug 2023
Aflibercept IPR Updates
Article
26 Jun 2023
Samsung Bioepis Files Four IPR Petitions On Alexion Eculizumab Patents And One IPR Petition On A Janssen Ustekinumab Patent
Article
19 Apr 2023
Accord BioPharma Announces The Acceptance Of BLA For HLX02 (a Proposed Trastuzumab Biosimilar) By FDA
Article
17 Mar 2023
Biogen Launches BYOOVIZ (Ranibizumab) In Canada
Article
08 Feb 2023
European Biosimilar Regulatory Updates